Clinical Trials Logo
  1. Home
  2. Methamphetamine Abuse
  3. NCT05593796
  4. Details
NCT05593796 Clinical Trial

Cognitive Behavioral Therapy(CBT) in Treatment of Methamphetamine Use Disorder

Methamphetamine Abuse Clinical Trial

Official title:
The Efficacy of Cognitive Behavioral Therapy(CBT) in Treatment of Methamphetamine Use Disorder

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT05593796
Other study ID # 715715
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 1, 2023
Est. completion date March 1, 2025

Study information
Verified date August 2023
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The efficacy of cognitive behavioral therapy(CBT) in treatment of methamphetamine use disorder

Description:

Methamphetamine (MA) use is a serious public health concern in many countries and is second to cannabis as the most widely abused illicit drug in the world. Over the past few years; there is an alarming increase in crystal methamphetamine (Shabu) abuse in the Egyptian market and The Egyptian government is annoyed from this issue because youth within the age of productivity were targeted. Regular methamphetamine use can be associated with a range of psychiatric symptoms, particularly psychosis, anxiety, and depression. No FDA approved pharmacological treatments are available for Meth addiction up till now and despite great advances achieved in understanding the neurobiology of drug addiction, the therapeutic options are severely limited . Consequently, the only available treatment at present is psychosocial intervention. The effectiveness of CBT for other substance-use disorders (e.g. alcohol-, opioid- and cocaine-use disorders) has been well documented and as such this basic treatment approach has been applied to amphetamine-type stimulant (ATS)-use disorder . Currently, there is not enough evidence to establish the efficacy of CBT for amphetamine -type stimulant( ATS) -use disorders because of a paucity of high-quality research in this area. The present study will examine the efficacy of Cognitive behavioral therapy in reducing methamphetamine use in comparison to medical treatment usually taken in methamphetamine use disorder

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 50
Est. completion date March 1, 2025
Est. primary completion date January 1, 2025
Accepts healthy volunteers No
Gender Male
Age group 15 Years to 50 Years
Eligibility Inclusion Criteria: - patients who meet the criteria for methamphetamine use disorder according to Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM 5) (10) - aged of 15-49 years' old - more than 9 year of education - urine drug screening positive for methamphetamine Exclusion Criteria: - other Axis I disorder of DSM-V criteria such as bipolar disorder, schizophrenia, depression - Had a legal case pending resulting in inability to commit to 12 weeks of treatment. - Refusal to participate - poly drug dependence.

Study Design

Related Conditions & MeSH terms

Intervention

Behavioral:
• cognitive behavioral therapy
12 weekly, individual sessions of manual-guided CBT delivered by trained clinician .

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Assiut University

Outcome
Type Measure Description Time frame Safety issue
Primary increase in the addiction severity index for methamphetamine use disorder 0-1 No imminent problem 2-3 slight problem 4-5 moderate problem 6-7considerable difficulty 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Recruiting NCT04927143 - Encouraging Abstinence Behavior in a Drug Epidemic Phase 2
Completed NCT03226223 - Pharmacogenetics of Naltrexone for Stimulant Abuse Phase 2
Completed NCT02907853 - Contingency Management for Meth in South Africa Methamphetamine Abuse in South Africa N/A
Recruiting NCT04616625 - Cardiovascular Effects of Prenatal Methamphetamine Exposure
Completed NCT04061941 - Change in Cognitive Function in Stimulant Users
Completed NCT01967381 - Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse Early Phase 1
Terminated NCT01019707 - Safety Assessment of Atomoxetine With MA IV Administration Phase 1
Completed NCT01011829 - Varenicline vs Placebo for the Treatment of Methamphetamine Dependence Phase 2
Active, not recruiting NCT04706624 - Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics N/A
Recruiting NCT05700994 - Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM) N/A
Completed NCT04109014 - FASTLANE II: Reducing Sex, Drug, and Mental Health Risk N/A
Completed NCT03336866 - Study of Antibody for Methamphetamine Outpatient Therapy Phase 1/Phase 2
Completed NCT01822132 - Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade N/A
Completed NCT01062451 - An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence Phase 1
Not yet recruiting NCT06233799 - Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder Phase 3
Recruiting NCT05521854 - Contingency Management for Drug Use: Does Age Matter? N/A
Completed NCT01063205 - NAC as a Potential Treatment for Methamphetamine Dependence Phase 1
Not yet recruiting NCT05334914 - ACT for Methamphetamine Use Disorder in Women and Gender Non-Conforming Individuals N/A
Terminated NCT05034874 - Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200 Phase 2